8-K: Eyenovia Amends At-the-Market Offering Agreement, Shifts Sales Agent to Chardan Capital Markets

Eyenovia, Inc. has amended its at-the-market offering agreement, replacing Leerink Partners with Chardan Capital Markets as the sales agent for up to $50 million in common stock.

Summary

• Eyenovia, Inc. entered into an Amended and Restated Sales Agreement with Chardan Capital Markets, replacing Leerink Partners as the sales agent for its at-the-market offering program.
• The company aims to sell up to $50 million of common stock through this program.
• Under the previous agreement with Leerink Partners, Eyenovia sold $16,413,443 of common stock.
• Chardan will receive a 3.0% commission on the gross sales proceeds of any stock sold.
• The offering will terminate when all shares are sold or the agreement is terminated.
• Eyenovia terminated its previous at-the-market prospectus with Leerink Partners on December 29, 2024.
• As of December 26, 2024, Eyenovia had $2.2 million in cash and cash equivalents.
• The company also owed $10.1 million in principal and accrued interest under a loan agreement.

Sentiment

Score: 5

Explanation: The document indicates a necessary capital raise, which is a neutral event. The company's low cash balance and high debt are concerning, but the new agreement provides a path for funding. The change of sales agent is not inherently positive or negative.

Positives

• The new agreement provides Eyenovia with a continued avenue to raise capital through the sale of common stock.
• The company has secured a new sales agent, Chardan Capital Markets, to manage the at-the-market offering.

Negatives

• The company has a relatively low cash balance of $2.2 million as of December 26, 2024.
• Eyenovia has a significant debt of $10.1 million as of December 26, 2024.
• The company is paying a 3.0% commission on gross sales, which will reduce the net proceeds from the offering.

Risks

• The company's ability to raise the full $50 million is not guaranteed.
• The company's low cash balance and high debt could pose financial challenges.
• The company is reliant on the at-the-market offering to raise capital, which may not be sufficient.
• The company's stock price is currently below the minimum bid price required by Nasdaq.

Future Outlook

The company intends to sell up to $50 million of common stock through the at-the-market offering program, but there is no guarantee that the full amount will be raised. The company will file a prospectus supplement relating to the offer and sale of the Common Stock pursuant to the A&R Sales Agreement.

Industry Context

At-the-market offerings are a common method for publicly traded companies to raise capital. The change in sales agent suggests a strategic shift in Eyenovia's approach to its equity financing.

Comparison to Industry Standards

• At-the-market offerings are a common practice for companies seeking to raise capital without the need for a traditional underwritten offering.
• The 3% commission is within the typical range for such offerings.
• The company's cash position of $2.2 million is relatively low compared to other companies in the pharmaceutical industry, which often require significant capital for research and development.
• The debt of $10.1 million is a significant liability for a company of this size and may be a concern for investors.
• Comparable companies that have used at-the-market offerings include XOMA Corporation and Agenus Inc., which have raised capital to fund clinical trials and operations.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• Employees may be impacted by the company's financial situation.
• Creditors will be monitoring the company's ability to repay its debt.
• Customers and suppliers may be affected by the company's financial stability.

Next Steps

• Eyenovia will file a prospectus supplement related to the offering.
• Chardan Capital Markets will begin selling shares of common stock.
• The company will continue to monitor its cash position and debt levels.

Key Dates

Keywords

at-the-market offering, common stock, capital raise, Chardan Capital Markets, Leerink Partners, sales agreement, cash, debt, equity financing